Axsome Therapeutics (AXSM) Net Cash Flow (2015 - 2026)

Axsome Therapeutics (AXSM) has 12 years of Net Cash Flow data on file, last reported at -$17.8 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 23.43% year-over-year to -$17.8 million; the trailing twelve-month figure through Mar 2026 stood at $4.2 million (up 113.74% YoY), and the FY2025 full-year result was $7.6 million, up 110.7% from the prior year.
• Net Cash Flow slipped to -$17.8 million in Q1 2026, from -$2.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $190.6 million in Q2 2023 to a low of -$54.8 million in Q1 2024.
• A 5-year average of $12.9 million and a median of -$11.3 million in 2022 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow surged 2687.71% in 2023 and tumbled 219.88% in 2024, its largest moves.
• Tracing AXSM's Net Cash Flow over 5 years: stood at -$26.7 million in 2022, then declined by 13.84% to -$30.4 million in 2023, then jumped by 60.53% to -$12.0 million in 2024, then surged by 80.49% to -$2.3 million in 2025, then sank by 662.16% to -$17.8 million in 2026.
• Business Quant data shows AXSM's Net Cash Flow at -$17.8 million in Q1 2026, -$2.3 million in Q4 2025, and $22.3 million in Q3 2025.